text: Yo, check it out, Coronavirus disease 19, COVID-19,
  It's a global pandemic, affecting folks with other pathologies, you see.
  We did some research, investigating the influence,
  Of treatments for osteoporosis and non-inflammatory rheumatic conditions, no coincidence.
  
  Osteoarthritis, fibromyalgia, we studied them too,
  See if they impact COVID-19, that's what we had to do.
  A cross-sectional study, 2,102 patients in our scope,
  Rheumatology Service of Hospital del Mar, Barcelona, Spain, we hope.
  
  From March 1 to May 3 in twenty-twenty,
  We compared COVID-19 incidence, man, it was plenty.
  Population estimates for the same city, we took into account,
  Used Poisson regression models, to see the relative risk amounts.
  
  Denosumab, zoledronate, calcium, they had a negative effect,
  COVID-19 incidence decreased, that's what we expect.
  But some analgesics, like pregabalin, and antidepressants too,
  They were positively associated, COVID-19 they'd ensue.
  
  Duloxetine, on the other hand, had a negative association,
  Reducing COVID-19 incidence, that's the revelation.
  Oral bisphosphonates, vitamin D, diuretics, anti-hypertensive drugs,
  And non-steroidal anti-inflammatory drugs, they didn't cause shrugs.
  
  No effect on COVID-19 incidence, that's what we found,
  In the population we studied, no impact all around.
  Our results bring new evidence, supporting the fight,
  To keep up the anti-osteoporosis treatments, day and night.
  
  Especially for elderly patients, affected by SARS-CoV-2,
  We gotta keep 'em safe, that's what we gotta do.
  So remember, maintain those treatments, it's crucial, understand?
  In the midst of this pandemic, let's lend a helping hand.